Terence Friedlander, MD

Terence Friedlander, MD

Assistant Clinical Professor, Division of Hematology/Oncology


Phone: (415) 476-4616 (appts)
UCSF Box 1711
San Francisco, CA 94143-1711

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member ยป Prostate Cancer

Research Summary

I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology these malignancies and in developing novel therapeutic ways to treat disease. I have collaborated with Dr. Pamela Paris over the last 6 years investigating advanced prostate and bladder cancer, particularly exploring the predictive value of circulating tumor cells (CTCs) in these malignancies. In addition to our work exploring CTCs as biomarkers of response and resistance, we have studied the structural and epigenetic state of advanced prostate cancer, and this work has led to a number of grants and publications. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number clinical trials in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work. This collaboration spans from the bench to the bedside, and I hope this work will help us to be able to predict which are likely to respond to neoadjuvant chemotherapy and allow us to tailor our clinical strategy to avoid giving toxic and ineffective therapies, and to select patients most likely to benefit.


Brown University, BA, 5/99
New York University School of Medicine, 2003, MD
UCSF Medical Center, 2003-2006, Residency
Utrecht University, Netherlands, 2007, Medical Ethics
UCSF Medical Center, 2007-2010, Oncology Fellowship

Professional Experience

  • 2009-2010
    Chief Fellow, Hematology and Oncology, UCSF
  • 2010-2011
    Clinical Fellowship in Urologic Oncology
  • 2011-current
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2006
    Fullfright Scholarship in Medical Ehtics, Netherlands-America Foundation
  • 2010
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2011
    ASCO Merit Award, American Society of Clinical Oncology
  • 2012
    Physician Research Training Aaward, United States Department of Defense
  • 2012
    Young Investigator Award, Prostate Cancer Foundation
  • 2012
    Young Investigator Travel Award, Advances in Circulating Tumor Cells Symposium

Selected Publications

  1. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct; 14(10):1213-1224.
    View on PubMed
  2. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 Sep 29.
    View on PubMed
  3. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 Sep 28; 380(1):144-52.
    View on PubMed
  4. Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. Urol Oncol. 2016 Aug; 34(8):356-67.
    View on PubMed
  5. Anantharaman A, Friedlander TW. A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2015 Dec; 68(6):946-8.
    View on PubMed
  6. Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, Premasekharan G, Tran T, Fu C, Ionescu-Zanetti C, Schwartz M, Fan A, Paris P. Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. J Urol. 2015 Sep; 194(3):790-8.
    View on PubMed
  7. Anantharaman A, Friedlander TW. The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks. Oncology (Williston Park). 2015 Jan; 29(1):67-8.
    View on PubMed
  8. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  9. Friedlander TW, Fong L. The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1104-6.
    View on PubMed
  10. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2014 May 15; 134(10):2284-93.
    View on PubMed
  11. Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2014 Jun; 142(3):271-80.
    View on PubMed
  12. Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol Clin North Am. 2012 Nov; 39(4):453-64.
    View on PubMed
  13. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012 Feb 1; 72(3):616-25.
    View on PubMed
  14. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9.
    View on PubMed
  15. Friedlander TW, Ryan CJ. Editorial comment. J Urol. 2010 Nov; 184(5):1976.
    View on PubMed
  16. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
    View on PubMed
  17. Friedlander TW, Ryan CJ. Novel hormonal approaches in prostate cancer. Curr Oncol Rep. 2009 May; 11(3):227-34.
    View on PubMed

Go to UCSF Profiles, powered by CTSI